Studies of human dendritic cells in the skin after antigen exposure by Bond, Emily
From Center for Infectious Medicine 
Department of Medicine 
Karolinska Institutet, Stockholm, Sweden 
 
 
 
STUDIES OF HUMAN DENDRITIC CELLS 
 IN THE SKIN AFTER ANTIGEN EXPOSURE 
 
 
 
 
Emily Bond 
 
 
 
 
Stockholm 2012  
 
  
 
All previously published papers were reproduced with permission from the publisher. 
 
Published by Karolinska Institutet.  
Printed by Larserics Digital Print AB, Sundbyberg. 
 
© Emily Bond, 2012 
ISBN 978-91-7457-932-1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
To my mother Monique and my grandmother Ebba,  
who both loved to read, and passed that love on to me.    
 
 
 
 
 
 
 
 
 
ABSTRACT 
Dendritic cells (DCs) act at the interface of innate and adaptive immunity. They are capable of inducing 
strong effector immune responses to invading pathogens, but also exert important functions in the 
maintenance of tolerance. The DCs of the skin are strategically located to be amongst the first cells to 
react to exposure to foreign substances and initiate immune responses, and increased understanding of 
these cells is critical for the development of new treatments of infections, allergic reactions and 
autoimmune disorders, as well as of new vaccine delivery strategies, targeting the skin. Studies of skin 
DC subsets are held back by technical difficulties in isolating the cells. In paper I of this thesis, we 
therefore aimed to develop a new DC purification method, using a skin graft mesher. This device is used 
clinically for expansion of skin graft tissue for transplantation. We found that by using the skin graft 
mesher the processing of skin was significantly accelerated, which had both practical and biological 
advantages. The DCs isolated from epidermis consisted of a uniform CD1a+ Langerin+ Langerhans cell 
population with high antigen uptake capacity. The DCs from dermis showed varied antigen uptake 
capacity and could be divided into three distinct populations based on CD1a expression. In addition, a 
skin explant model to study antigen uptake by DC subsets in situ was developed. We found that antigen 
injected into the skin explants was rapidly taken up, mainly by DCs in the dermis. This model can be a 
useful tool to study immediate responses to antigen exposure. However, since no recruitment of new cells 
into the tissue can occur, skin explants cannot illustrate all the components of innate immune responses. 
This prompted for the studies in paper II and III, where we took the approach to study infiltration of 
DCs to sites of antigen exposure in the skin in vivo. By using skin punch biopsies collected from standard 
skin antigen test sites like the tuberculin skin test (TST), we quantified recruited immune cells by 
immunohistochemical stainings of cryosections. We found that several DC subsets including 
plasmacytoid DCs (pDCs) accumulated in the dermis in the indurations induced in individuals with 
positive TSTs. In contrast, donor-matched saline injected skin did not show any DC recruitment, nor did 
TST sites of individuals lacking induration. The positive TST induration tissue was also associated with 
cell death and high expression of the antimicrobial peptide LL37, which together can provide a means for 
pDC activation and IFN! production. In line with this, IFN-inducible MxA was highly induced at the 
positive TST sites. By in vitro experiments, we found that pDCs were not as efficient as myeloid DC 
subsets to take up the TST antigens. Further, IFN! containing supernatants from pDC activated with 
LL37-DNA complexes reduced antigen uptake in myeloid DCs as well as decreased their capacity to 
activate T cells. Infiltrating pDCs in the TST reaction may thus have a regulatory effect upon the antigen 
processing and presentation functions of surrounding DC subsets, to limit potentially detrimental and 
excessive immune stimulation. TST and other antigen skin tests are used to monitor the integrity of the 
cellular immune system in HIV-1 infected individuals. To evaluate whether mobilization of DCs in 
response to antigen skin tests was impaired in HIV-1 infected individuals, we analyzed skin punch 
biopsies from skin test sites using mumps virus, Candida albicans or TST. Control skin biopsies showed 
that there was no difference in the number of skin-resident DCs between healthy and HIV-1 infected 
individuals. Also, multiple DC subsets infiltrated the dermis in response to injection with all antigens. 
However, the levels of DC infiltration correlated with the generally lower levels of memory T cells that 
accumulated at the antigen sites. A depleted or deficient T cell compartment could therefore lead to 
compromised DC recruitment and insufficient antigen presentation to T cells. Taken together, these 
studies contribute with new methods and data on the function and phenotypes of skin DCs, and their 
response to antigen administration in the skin in health and HIV-1 infection. 
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1 INTRODUCTION 
Understanding the immune system is at the very heart of understanding human 
physiology and pathology. The delicate balance of the immune system is absolutely 
crucial to our survival, from the very beginning of life by allowing attachment of the 
fertilized egg to the uterine wall, through growth processes, destruction of defective 
cells that could turn cancerous, healing of wounds and broken bones, to the most 
obvious task of protecting us from foreign invasion in the shape of various microbes. 
While many questions about human immunology have been answered, many remain. 
Increased knowledge of key components of the immune system is crucial to 
understand, prevent and treat infectious diseases and autoimmune disorders. The work 
presented here focuses on a subset of immune cells called dendritic cells (DCs).     
                                                                                                                                           
DCs are at the interface of innate and adaptive immunity and are key cells for initiating 
immune responses. Understanding more about these cells, including how they collect 
antigens from pathogens or vaccine formulations, could help us manipulate their 
subsequent stimulation of effector cells in the desired direction i.e. toward antigens 
derived from threatening infections, but away from self antigens and autoimmune 
disease. For the scientific community to reach this level of understanding, many issues 
regarding the study of DCs remain. These relate to challenges in both methodology and 
sample material. The studies included in this thesis involve refinement of methods to 
isolate DC subsets in human skin, which also includes characterization of some of the 
phenotypical and functional differences of these subsets. Following on from this, in situ 
investigation of recruitment of DC subsets to sites of antigen administration in the skin 
were performed using unique skin biopsy material. This enabled studies of how DCs 
infiltrate the skin after antigen exposure and identification of factors in the environment 
that could contribute to cell activation. Finally, by using similar skin biopsies from 
HIV-1 infected individuals, alterations in DC recruitment in response to antigen 
exposure could be examined. All studies in this thesis were performed using human 
cells and skin and I only refer to human cells in the text, unless otherwise specified. 
                                                                                                                                             
The first part of this thesis is dedicated to provide a background for our studies. A 
general introduction to the human immune system, with the main focus on innate 
immunity, is followed by a description on specific immune cells and processes in the 
skin. The various subsets of DCs and their properties are then introduced. To provide a 
background for our studies on HIV-1 infected individuals in the final paper, a short 
introduction to HIV-1 and DCs in HIV-1 infection is also provided. The second part of 
the thesis includes a presentation of the materials and methods used in our studies, and 
the results presented together with a discussion of our findings. Included at the end are 
the three papers on which this thesis is based. 
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2 AIMS OF THESIS 
The studies in this thesis have focused on the isolation and identification of specific 
dendritic cell subsets in human skin, and their response to antigen exposure in various 
settings. The more specific objectives were:                  
 
Paper I:     To develop an efficient isolation protocol for human dendritic       
                   cells from skin, and to phenotypically and functionally characterize the cells 
                   with a focus on antigen uptake capacity.  
 
Paper II:    To study the recruitment and function of dendritic cells in the  
                    positive tuberculin skin test (TST). 
                                      
Paper III:   To compare recruitment of dendritic cells in response to skin antigen tests   
                    in healthy versus HIV-1 infected individuals.  
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3 THE HUMAN IMMUNE SYSTEM 
3.1 WHAT’S IN A NAME? 
The immune system is subdivided into innate and adaptive immunity. As suggested by 
the very name, the innate immunity is what we were born with. The capacities of this 
branch of the immune system are genetically predetermined, encoded in our germ-line 
(1). The advantage of this is that it benefits from evolution through natural selection to 
be as efficient as possible in defining and annihilating invasive microorganisms. The 
disadvantage is that we can only carry so much genetic load; hence the innate immune 
system cannot carry memory of all possible pathogenic structures. It therefore needs 
completion by the almost infinite variety of specificities of the cells of the adaptive 
immune system. While these cells are naturally also inborn, their respective 
specificities are not. The greatness of their diversity has the drawback of not being 
germ-line encoded; hence their lessons have to be relearned by every generation (2). 
Another major difference between the branches is that it takes several days for a 
complete activation of the adaptive immune response, time that we do not have when 
exposed to an infection. In contrast, the innate immune response is instantaneous and 
can hold the fort while clonal expansion and maturation of the adaptive immune cells 
takes place, forming a specific response that in most cases eventually clears the 
infection. The capacity of the adaptive immune system to form immunological 
memory, thereby preventing reinfection with the same pathogens and making 
vaccination strategies possible, is another great ability of this branch (3). In conclusion, 
the innate and adaptive branches of immunity have intrinsic qualities that complement 
each other.  
 
3.2 INNATE IMMUNITY 
Innate immunity is usually described as including all the non-specific cells and 
components of our immune system. Even our physical barriers to the outside world, the 
skin and mucosal surfaces, and the tight junctions holding them together, as well as 
mucus, tears and the cilia of the nasal cavity and respiratory tract are often included (4). 
Several other non-cellular components, like the proteins of the complement activation 
cascade, contribute to the initiation of inflammation and the clearing of invading 
pathogens. Natural killer cells (NK-cells), clearing both infected and cancerous cells 
from the body, are considered part of the innate immune response since their response 
is instant and non-specific. They have, however, recently been suggested to be able to 
form memory-like responses (5), a capacity previously thought to be characteristic for 
cells for the adaptive immune system. In the studies included in this thesis, some parts 
of the innate immune response have been studied more closely.  
   
3.2.1 Antimicrobial peptides 
The antimicrobial peptides (AMPs) constitute an evolutionarily ancient part of the 
innate immune system (6), and their importance and relevance to many pathologic 
conditions is being increasingly appreciated (7). They are characterized by being small, 
less than 100 amino acids long, and are able to kill both gram-negative and gram-
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positive bacteria, fungi and enveloped viruses (8, 9). They are produced by a wide 
range of cells, including epithelial cells, neutrophils, macrophages, platelets, 
lymphocytes, DCs, and mast cells (4). Some are constitutively expressed and others are 
induced by inflammatory cytokines. They are bactericidal, immune-regulatory, and also 
seem to have important roles in wound healing and angiogenesis (10). The main three 
classes of AMPs in humans are defensins, cathelicidins and histatins. The defensins 
lyse bacteria, fungi and some enveloped viruses, by inserting a hydrophobic region into 
the lipid membrane of the microbe, disrupting the integrity of the membrane. Apart 
from the capacity to directly kill invaders, the defensins act as chemoattractants for 
other immune cells, and can have stimulatory effects on DCs (11). There is only one 
human cathelicidin, an 18 kDa cationic protein named hCAP18. It is produced mainly 
by leukocytes, epithelial and mucosal cells. When activated, a cationic carboxy-
terminal is cleaved off to form LL-37, a peptide with a wide range of properties. Apart 
from, like the defensins, being able to directly lyse microbial cell membranes, LL-37 is 
chemotactic, induces histamine release and angiogenesis. It is also upregulated in 
wound healing, and is suggested to play a role in the pathogenesis of autoimmune 
disease, as well as by its immune-regulatory properties affect our ability to respond to 
cancers (8, 9, 12, 13). Both defensins and LL-37 are secreted by, and interact with, 
keratinocytes, and are therefore of great interest in cutaneous immunobiology (10). The 
third class of human antimicrobial peptides, the histatins, are mainly expressed in the 
oral cavity and have antifungal effects (14). 
 
3.2.2 Phagocytes 
As ever, somebody has to clean up, and in the body it is the phagocytes. Apart from the 
physical engulfing of non-desired material (namely live or dead pathogens, and 
apoptotic or necrotic cells from our own body), they act on a wider plane sounding the 
alarm, alerting components of both the adaptive and innate immune response, as well as 
non-immune cells, to the danger at hand (1). They do this via release of pro-
inflammatory cytokines and other substances. There are three major classes of 
phagocytes; macrophages and monocytes, granulocytes and DCs. Macrophages are 
tissue resident or can mature from circulating monocytes being recruited to inflamed 
tissues, and are highly phagocytic (15). Macrophages in different tissues have been 
assigned different names, e.g. microglia in the central nervous system or Kupffer cells 
in the liver, but they all belong to the same class (1). DCs, discussed in detail in section 
5 of this introduction, can belong to this class but will much more often be referred to 
as constituting their own. The granulocytes share the feature of distinct cytoplasmic 
granules consisting of molecules and enzymes ready for release to limit infection, and 
include neutrophils, eosinophils, basophils and mast cells. They are important early 
responders to infection, but are also important in the pathogenesis of allergic disorders 
(16).  
 
3.2.3 Immune recognition 
The cells of the innate immune system recognize pathogens by identifying pathogen 
associated molecular patterns (PAMPs) on their surface. These patterns are highly 
conserved regions that large groups of microbes share. The patterns are recognized by 
pattern recognition receptors (PRRs) which can be soluble, like Mannan-binding lectin 
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(MBL) – specifically binding terminal mannose residues present on many 
microorganisms, and C-reactive protein (CRP) or ficolins that are able to activate the 
complement cascade when encountering their ligands (17, 18), or cellular. There are 
many types of cellular PRRs, some are found on the cell surface, others in the 
cytoplasm. One of the main functions of the cell surface C-type lectin family of 
receptors is pattern recognition, with ligation triggering internalization of the antigens. 
Macrophage mannose receptor (MMR, or CD206) recognises a wide range of bacterial, 
viral and fungal pathogens and stimulates their phagocytosis (19), and DEC-205 
(CD205) seems to have similar functions (17). DC-SIGN (CD209) detects a wide range 
of pathogens, and has importantly been shown to detect gp120 from HIV-1 and mediate 
its uptake to promote trans-infection of the virus (20). Langerin (CD207) has been 
shown to bind fungi, mycobacteria and viruses, including HIV-1 (21). The role of the 
receptor in transmission of HIV-1 is however not clear, with some conflicting evidence 
as to its function (22). Another example of an endocytic PRR is the macrophage 
scavenger receptor (MSR) which recognises viral double-stranded RNA, as well as 
lipopolysaccharide (LPS) and lipoteionic acid (LTA) from bacterial cell walls (23). In 
the cytosol, NOD-like receptors (NLRs) NOD and NALP have been described, which 
are activated in response to exposure to bacterial peptidoglycans, and in the case of 
NALP also to DAMPs (24). Nalp3 has been identified as the receptor activated by 
aluminium adjuvants (alum), the most commonly used vaccine adjuvant (25). Retinoic 
acid-inducible gene I (RIG-I)-like receptors are also found in the cytosol, and respond 
to viral RNA (24).  
                                                                                                                        
The most well described cellular PRRs are the toll-like receptor (TLR) family. They are 
expressed on many cell types, including macrophages, DCs, B cells and some epithelial 
cells (26). Despite the fact that there are relatively few TLR genes, the specificity with 
which they recognize highly conserved regions (usually essential for survival or 
pathogenicity) on various classes of microbes, enables them to identify most 
pathogenic microbes. There are 10 TLRs described in humans, together detecting a 
wide variety of PAMPs, e.g. lipopolysacceride (TLR4), bacterial lipoproteins and 
lipoteichoic acids (TLR2), flagellin (TLR5), unmethylated CpG DNA from bacteria 
and viruses (TLR9) and single-stranded viral RNA (TLR7) (26). While most TLRs are 
found on the cell surface, TLR3 and 7-9 are instead situated in endosomal 
compartments. All TLRs share the common characteristic of being trans-membrane 
proteins with an extracellular region composed of leucine-rich repeats that creates a 
horse-shoe shape protein that is adaptable for ligand binding (27). The correct ligand 
will cross-link the ectodomains of two TLRs (either two of the same kind, or 
heterodimers of TLR1/2 or TLR 2/6), making their intracellular domains come together 
which in turn will activate different pathways of intracellular signalling, depending on 
the specificity of the TLR (17, 27, 28). This allows the different TLRs to steer the 
resulting cytokine production to either a strong antiviral, or antibacterial response, 
depending on the predominant ligands the cells was exposed to. A common 
characteristic of the patterns recognized by the TLRs is that they are considered specific 
for pathogenic structures. This makes the innate immune response specific for 
infection, and since the adaptive immune response has to be activated by the antigen 
presenting cells (APCs) of the innate immune system, this is a vital step to prevent 
autoimmune reactions. While the APCs presents both self and microbial antigen to the 
T cells, a co-stimulatory signal, induced by TLR ligation, is needed to activate the T 
  6 
cells. No rule without an exception though - here it is the capacity of TLR7 and TLR9 
to bind nucleic acids, which is a component of healthy mammalian cells as well as 
certain viruses. The protection mechanism here is that ssRNA is normally not present 
in endosomes, where TLR7 and TLR9 are found (26), but it has been shown that this is 
not enough – the signalling of host ssRNA through TLR7 and 9 seems to be involved in 
the pathogenesis of autoimmune disease (discussed in detail in paper II) (29, 30). 
Important from a cutaneous perspective is the fact that activation of most TLRs drives 
activation of CD4+ T cells to a TH1 phenotype, protecting from atopic reactions in the 
skin (31). The use of synthetic TLR ligands for modulation of the immune response in 
vitro or in clinical settings is a promising field both when it comes to treatment of 
disease and development of new vaccine strategies. For example, the TLR7 ligand 
Imiquimod is already in clinical use to treat condylomas, and in pre-clinical testing as 
vaccine adjuvant. 
 
3.3 ADAPTIVE IMMUNITY 
As opposed to the cells of the innate immune system, the major effector cells of the 
adaptive immune system, T cells and B cells, have an almost infinite variety of 
specificity of their receptors to recognise invading pathogens. These receptors are 
generated during development of the cells, by random gene rearrangements of germline 
encoded segments called variable (V), diversity (D) and junction (J). In addition to the 
random combination of the genes, the junctions at which they are combined also varies, 
and all this provides almost endless variations of the T cell receptor (TCR) and the 
immunoglobulin receptor of the B cell (32). The fact that the receptors are created in 
this random fashion means that the genetic code for the receptors is not transferred 
between generations, but every individual has to build their own adaptive immunity to 
every pathogen they are exposed to, a fact painfully obvious to all parents of young 
children. Another effect of the receptors being created randomly is that many of them 
will be reactive to self-Ag. To prevent these self-reactive receptors from ever being 
activated and thereby causing autoimmune reactions, there are many check points to 
pass before a B or T cell receptor is allowed to activate its host cell, both in the bone 
marrow and thymus and in the periphery. One of the most important functions of the 
DCs is the initiation of adaptive immune responses by presentation of antigen to T 
cells, a process that in the absence of activation signals is also important for 
maintaining tolerance (33).  
 
3.3.1 Antigen presentation 
For T cells to be activated and develop into strong effector cells, they need to be 
presented to antigens on MHC class I or MHC class II. Both receptors are produced in 
the ER, and consist of an ! and a " chain, arranged differently on the receptors, with the 
antibody binding cleft of the MHC class I being formed by ! chain segments only, and 
the MHC class II being formed by segments of both ! and " chains (1). MHC class I is 
expressed on all cells in the body, except red blood cells, and presents intracellular 
antigens mainly to CD8+ T cells. MHC class II on the other hand is only present on 
APCs, the most potent being the DCs, and will display exogenous antigen that has been 
taken up by endocytosis or macropinocytosis and processed within the cell. The MHC 
II/antigen complex is mainly recognised by CD4+ T cells. Activation of CD8+ T cells 
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will lead to lysis of the cell presenting the antigen, thus killing the intracellular 
pathogen along with the cell. CD4+ T cell activation by the MCH class II, on the other 
hand, will save the cell, but through the effects of the CD4+ T cells alert surrounding 
cells to the fact that there are pathogens in the extracellular space (34). Hence, there is a 
very functional basis to which T cells respond to which MHC. To prevent MHC class II 
from taking up intracellular proteins on its way from the ER, the antigen binding cleft is 
covered by an invariant chain, that will be cleaved of in the acidic milieu of the 
endosome taking the molecule to the cell surface (1). In some instances though, MHC 
class I can present extracellular antigens, after these have been taken in by endocytosis, 
in a process called cross-presentation. In this process, APCs are able to induce 
cytotoxic T cell responses to microbes that do not infect the APC itself by taking up 
extracellular antigens and presenting them on MHC class I. Cross-presentation is more 
common in some DC subsets than others (discussed in 5.4.1), and is enhanced by TLR 
ligand stimulation of the DCs (35, 36). 
Lipid antigens can also be presented on CD1 molecules. In humans CD1a-d have been 
defined, and are expressed on some dendritic cells and monocytes (37). Glycolipids are 
non-covalently bound to a hydrophobic cleft of the molecule and the complex can be 
recognised by the TCR of various T cell subsets (38).  
  
3.3.2 T cells 
As described above, the T cell receptor (TCR) is greatly variable; it is estimated there is 
roughly a billion unique TCRs in the naïve T cell population (39). To prevent variants 
that are reactive to self-antigens, the T cells go through rigorous control in the thymus, 
where they mature from their lymphoid progenitors (hence the T), before they are 
allowed out into the body (3). If a self-reactive T cell slips through the thymus tests and 
binds a MHC-self antigen-complex, the cell presenting the complex will not give the T 
cell any secondary activating signal (as an infected, or by other means activated, cell 
would), which will rendered the T cell anergic and incapable of further maturation to an 
effector cell (33). In case of a T cell encountering a non-self-MHC-complex for which 
it is specific, and receiving co-stimulatory signals from the activated APCs, it will be 
activated to undergo clonal expansion, and to in turn exert activating effects on B cells 
and other surrounding immune cells. 
 
Figure 1. CD4 T cell activation by dendritic cells. The activation signal is provided in three steps: 1) 
Presentation of antigen on MHC class II, recognized by the TCR. 2) Binding of co-stimulatory molecules 
of the B7 family upregulated on activated DCs to CD40 on the T cell surface. In the absence of this 
signal, the T cell will be rendered anergic. 3) Cytokines from the DC and the local environment provide 
the final signal, and also determine the phenotype of the mature T cell.  
Naïve CD4+ T cell 
IL-12, IFN! 
IL-4 
TGF" 
TGF", IL-6 
IL-6 
1 
3 
2 
DC with antigen 
for MHC class II 
presentation   
Th1 cells 
Th2 cells 
T regulatory cells 
Th17 cells 
T follicular helper cells 
Cytokines present during the activation of the Th 
cell determine the phenotype of the mature cell. 
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Cells of the CD4+ phenotype are also referred to as T helper (TH) cells, and can be 
further subdivided into TH1 type or TH2 type. TH1 are major controllers of cell-
mediated adaptive immunity, with capacity to help CD8+ T cell precursors differentiate, 
activate macrophages, boost the cytotoxic effects of NK cells and activate B cells. TH2 
cells induce humoral immunity to extracellular pathogens, like extracellular bacteria, 
fungi or parasites. They stimulate antibody production, and activate eosinophils, 
basophils and mast cells (32). TH1-TH2 balance is often discussed in models of 
autoimmune disease and atopic/allergic disease, with the TH2 phenotype often 
predominating in patients with such conditions (32). If the CD4 is exposed to IL-6 or 
TGF" during activation, it can take on a TH17 phenotype, described to be efficient in 
defence against certain extracellular bacteria, but also to mediate autoimmune disease 
and chronic allergic processes (3). Another T cell type with important immune-
regulatory function is the regulatory CD25+CD4+ T cell. It secretes immunosuppressive 
cytokines, and downregulates both TH1 and TH2 T cell activity. CD8+ T cells recognise 
MHC class I:antigen complexes, and when activated by co-stimulatory receptors 
assume a cytotoxic effector phenotype capable of lysing the target cell by granzymes 
and perforin, which form a complex that perforates the cell membrane of the target cell 
so that is undergoes apoptosis. Like their CD4+ counterpart, CD8+ T cells also produce 
multiple cytokines to affect surrounding tissues and immune cells. Natural Killer T 
cells (NKT) are a subset of cells with a TCR, but also with NK cell lineage markers. 
They recognise lipid antigen on CD1 and seem to inhibit autoimmunity (32). 
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4 THE SKIN AS AN IMMUNE ORGAN 
4.1 ANATOMY OF THE SKIN 
The skin is the largest organ of the body and, along with the mucosal surfaces, is what 
separates us from the outside world. The protection by the skin from bacteria, viruses, 
fungi and parasites is physical and chemical as well as immunological. The skin also 
helps regulate body temperature by the sweat glands capable of releasing water to cool 
the body, and the hair follicles capable of creating air pockets between hairs to warm 
the skin – both features involved in regulating the effects of pyrogenic cytokines in 
infectious disease. The most prominent layers of the skin are the epidermis and the 
underlying dermis (Figure 2), separated by a basement membrane. While the epidermis 
is avascular, the dermis harbours fine capillary networks and lymphatic plexus. The 
epidermis consists mainly of keratinocytes, sealed by tight junctions. The keratinocytes 
proliferate from the base of the epidermis, and loose their nuclei as they are being 
pushed up, by new proliferating keratinocytes, to become part of the dead cornified 
epithelium, or stratum corneum – the outermost layer of the skin. This consists of cross-
linked dead keratinocytes (referred to as corneocytes) embedded in a lipid matrix with 
ceramides, cholesterol and antibacterial free fatty acids. Interspersed in the epidermis 
are, importantly, the Langerhans cells, and also the melanin producing melanocytes, 
which protect us against UV radiation. The dermis is less cell-dense than the epidermis. 
It has a collagen structure, and is home to fibroblasts, capillary networks, c-fibre nerve 
endings, as well as dermal DCs (dDCs), macrophages, memory T cells and other 
important actors of the immune system (40). Interestingly, the expanding field of 
neuroimmunology has demonstrated several important functions of the peripheral c-
fibre nerve fibres in the regulation of cutaneous immunity (41), again showing how 
intricate the regulation of immune responses is.  
 
 
 
Figure 2. Basic anatomy of the skin. The brown staining represent CD1a+ DCs. The cell nuclei are 
visualized in blue by haematoxylin counterstaining.  
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4.2 FRIENDLY LANDLORD AND FIERCE DEFENDER 
Although the skin is critical for protection of pathogens, it also hosts countless so-
called commensals, which are non-pathogenic bacteria. These useful tenants help 
protect us from pathogenic bacteria by competing with them for nutrients and space. 
Some even produce antibacterial substances (42). The challenge for the immune system 
of the skin is hence to balance the protection of the commensal flora with the capacity 
to respond with immune activation upon encountering pathogenic microbes. The 
Langerhans cells (LCs) of the epidermis (described in detail in 5.4.2.) are thought to 
play an important role in maintaining this balance by extending dendrites through the 
tight junctions of the keratinocytes in the stratum corneum (43) to sample and present 
antigens from the commensal flora to T cells in a fashion that builds tolerance (44-46). 
In immune responses to invading pathogens, the skin shares its immune features with 
most other tissues in the body, but there are some cell types and concepts that are more 
or less skin specific, or have very defined missions in the skin.  
 
4.3 INNATE IMMUNITY IN THE SKIN 
While keratinocytes can be found in other areas of the body, they are uniquely 
abundant in the skin, where they comprise the principal cell type of the epidermis. 
Apart from the barrier function described earlier, and their role as scaffolding i.e. 
providing the actual structure of the epidermis, they have important immune-regulatory 
properties. They produce a wide range of cytokines, can be activated to present 
antigens, and also produce antimicrobial peptides; "-defensins and the cathelicidin LL-
37, which are packed in lamellar bodies and released into the lipid matrix of the 
epidermis (10, 47, 48). They also, through cytokines, growth factors and hormones, 
influence the function and phenotype of the epidermal resident LCs (49). To ensure 
regeneration of the keratinocytes after abrasions to the skin, hair follicles contain 
protected repositories of epithelial stem cells capable of regenerating superficial skin 
layers (50). Another major effector in the skin is the mast cell, a bone marrow derived 
granulocyte, which is resident in the dermis. Mast cells are normally located 
perivascularly and respond early to inflammation. They are easily activated and exert 
rapid and strong inflammatory responses, and urticaria, by the release of leukotriens 
and histamine (51). As anywhere in the body, the endothelial cells in the skin are highly 
active in immune responses as well. To allow recruitment and migration of immune 
cells, activated endothelium increase their permeability by loosening tight junctions and 
upregulating VCAM-1 and ICAM-1, which binds immune cells in the circulation to 
slow them down and allow diapedesis (the migration of cells through the junctions 
between the endothelial cells). Expression of selectins on activated endothelium further 
enhances migration of lymphocytes (52). 
 
4.4 ADAPTIVE IMMUNITY IN THE SKIN 
Adaptive immune responses in the skin are activated by the cells and components of 
their innate counterparts. There are few resident T cells in the skin, but in cutaneous 
inflammation E-selectin is specifically upregulated, which attracts CD45RO+ memory 
T cells expressing cutaneous lymphocyte antigen (CLA) (53) which binds E-selectin. 
CLA+ T cells are specific for antigens that were initially presented to them by APCs 
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(mainly DCs) derived from the skin (54-56). Therefore, specific recruitment of these T 
cells to the skin facilitates adaptive cellular responses including memory T cells 
specific for the invading pathogens targeting the skin. In fact, low constitutive 
expression of E-selectins and ICAM-1 on skin endothelial cells ensures that there are 
also memory T cells consistently present in the skin, ready for potential invasion (57). 
If a naïve T cell is activated by a DC that has migrated from the skin to the lymph node, 
the T cell is prone to upregulate CLA, and also CCR4, CCR6, CCR8 and CCR10, the 
ligands for which are induced in inflamed skin (52). The activated naïve T cell will then 
find its way to the skin by interaction of CLA and E-selectin, as does the memory T 
cell. This process of T cell attraction is referred to as “homing” (58).   
 
 
 
Figure 3. Schematic illustration of the adaptive immune response in skin, inspired by (34).  
 
4.5 DELAYED TYPE HYPERSENSITIVITY SKIN TESTS 
Delayed type hypersensitivity (DTH or type IV hypersensitivity) is a T cell-mediated 
reaction to antigens to which an individual is sensitized i.e. has previously been 
exposed to. DCs in the skin take up and present antigens to either skin resident or 
circulating memory T cells (the latter recruited to the site by migratory DCs presenting 
in lymph nodes). This initializes an inflammatory reaction, including homing of cells to 
the site of antigen exposure, which usually peaks at 48-72 hours. The classic example 
of such reactions is the Mantoux text or tuberculin skin text (TST), where purified 
protein derivate (PPD) from Mycobacterium tuberculosis (MTB) is injected 
intradermally to test for previous exposure to the antigen or its vaccine Bacillus 
Calmette-Guérin (BCG), or used for monitoring of the disease (59). In addition, the test 
can be used to evaluate the function of the cellular immune system in immune-
compromised individuals. For this purpose other antigens than PPD can also be used, 
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such as mumps virus or Candida albicans, which a large majority of the population has 
been exposed to through infection or vaccination. These clinical tests consist of an 
intradermal injection of antigens, and after 48 hours the diameter of the induration that 
may occur at the site is measured. A test is considered positive at a diameter #10 mm 
according to WHO standards, and sometimes at # 5 mm in clinical settings where 
tuberculosis exposure would be low. As discussed further in paper III, skin antigen tests 
have been used to monitor the integrity of the cellular immune responses in HIV 
infection (60, 61), and the TST has been demonstrated to be an independent predictor 
of disease progression (61-64). 
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5 DENDRITIC CELLS 
5.1 SENTINELS OF THE IMMUNE SYSTEM 
Dendritic cells (DCs) are often thought of as the sentinel guards of the body. Some 
subpopulations of DCs are situated in the skin and at mucosal linings, sites where we 
are frequently exposed to pathogens. This enables DCs to quickly respond to 
pathogen exposure, but likely also to help the body maintain tolerance to the 
commensal bacteria at theses sites (65). Other DC subsets are found in the 
bloodstream and in secondary lymphoid organs during steady state but can be 
recruited to peripheral sites of pathogenic exposure, and/or inflammation, by 
cytokine/chemokine gradients and selectins. The various DC subsets have different 
specializations and profiles, but share some key features. Most importantly, they are 
all antigen presenting cells (APCs). Some DC subsets are more efficient than others 
to activate CD4+ and CD8+ naïve T cells, and to dictate the subsequent type of 
immune response elicited by these cells (66). They can also directly activate B cells, 
NK cells and NKT cells (67) and by release of pro-inflammatory or regulatory 
cytokines affect multiple other cell types. Since DCs respond quickly to pathogen 
exposure and have the capacity to present antigen and produce regulatory cytokines, 
they are key cells for orchestrating the development of immunity.  
 
5.2 ANTIGEN UPTAKE PATHWAYS 
DCs take up antigen by two major pathways, phagocytosis and pinocytosis. 
Phagocytosis means engulfment of large particulate antigens, such as bacteria, yeasts, 
protozoans and dying cells. Pinocytosis can be subdivided in macropinocytosis and 
receptor-mediated endocytosis. Macropinocytosis, internalization of soluble antigens, 
occurs continuously in immature DCs and is non-specific (68). Receptor-mediated 
endocytosis, on the other hand, requires ligation of antigens to a specific surface 
receptor such as C-type lectin receptors, scavenger receptors or Fc receptors 
(recognizing the Fc portion of antibodies) (69, 70). The mode of uptake of an antigen 
influences the intracellular events following internalization (71, 72). Large particulate 
antigens taken up by phagocytosis remain in a phagosome, which will become 
increasingly acidic leading to degradation of the antigen and allows for loading of 
peptides onto MHC molecules. Macropinocytosed antigen, and antigen taken up by 
endocytosis via receptors linked to MHC class II-restricted presentation, will be 
directed to lysosomes for degradation and loading on MHC II. There are also 
receptors linked to cross-presentation, and antigens taken up after ligation to such 
receptors will instead be directed to stable early endosomes for loading on MHC class 
I (36).  
 
5.3 ACTIVATION, MATURATION AND MIGRATION 
The antigens taken up by the DCs can contain danger-signals like PAMPs from 
pathogens, or danger-associated molecular patterns (DAMPs) from self-antigens of 
distressed cells (e.g. heat shock proteins, HMGB-1, "-defensins and uric acid). These 
signals are sensed by PRRs, as described earlier. Different subsets of DCs have 
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different expression repertoires of PRRs (26, 73, 74). Ligation by a danger signal to a 
PRR activates the cell to undergo a process of maturation. This constitutes a wide 
range of morphological and functional changes, including; 1) loss of adhesive 
molecules and the acquisition of high cellular motility – to be able to migrate to 
lymph nodes and present their antigen, 2) loss of endocytic and phagocytic receptors 
– to reduce the ability of the DC to take up and present additional antigen while 
activated which could break the immune tolerance to self antigens, 3) upregulation of 
co-stimulatory receptors (B7 family) including CD80 and CD86 – enabling the DC to 
potently activate T cells by interaction with CD28 on the T cell surface, and 4) 
secretion of a large variety of cytokines that will strongly affect the nature of the 
immune response elicited (67). In a rapid response to stimulation, even before 
undergoing complete maturation, the DCs release chemokines, e.g. CXCL1-5 and 9-
11, directing other immune cells to the site. The first wave of chemokines produced 
attracts immune cells such as NK cells, neutrophils, memory T cells and monocytes. 
This helps create an inflammatory milieu harmful to the intruder and beneficial for 
recruitment of additional immune cells. As DCs mature they upregulate receptors that 
will guide them to the secondary lymphoid organs via lymphatic vessels. This enables 
DCs to interact with and migrate through the high endothelial venule (HEV) walls of 
the lymph nodes. One of the main receptors is CCR7. Once in the lymph node, DCs 
will secrete a second wave of chemokines: CXCL13 to attract B cells and T follicular 
helper cells (specialized to support the development of humoral responses), CCL19 
and CCL21 to attract naïve T cell, and CCL22 – attracting T regulatory cells (67). 
Now in close contact with T and B cells, the DCs can present their antigen and 
thereby elicit an antigen-specific immune response (discussed in more detail in 
section 3.3.3). If, in contrast, the DC has taken up an antigen not associated with a 
PAMP or DAMP motif to activate the DC, the antigen will be presented to T cells in 
the absence of co-stimulatory molecules. Antigen presentation without accompanying 
co-stimulatory stimulation will render the T cell anergic and incapable of developing 
into an effector cell. This is a way to protect the body from self-reactive T cells (75). 
The antigens presented in this tolerogenic fashion are often host-derived, but may 
also represent antigens from the commensal flora present in skin and mucosal linings. 
As mentioned above, LCs at these sites are thought to sample the commensal flora by 
sampling the outer lining of the skin and mucosa, and present their antigens in a 
tolerogenic fashion (43, 76). In addition to this; if exposed to the suppressive 
cytokines IL-10 and TGF-", immature DCs in lymphoid tissue can regulate immune 
responses further by inducing unresponsiveness in peripheral T cells (77, 78). DCs also 
have the capacity to induce regulatory T cells that produce IL-10 (79, 80) or Foxp3+ 
regulatory T cells (81). Taken together, DCs have been shown to have the capacity to 
direct the immune system in both activating and tolerogenic directions. 
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5.4 DENDRITIC CELL SUBSETS 
The DC subsets presented below are divided into blood or skin resident DCs. However, 
it is important to note that DCs are migratory cells and multiple DC subsets can be 
recruited to inflamed tissues. 
 
Figure 4. The human DC subsets in skin and blood, and their main phenotypic characteristics.  
 
5.4.1 Subsets in blood 
The main DCs subsets in blood are myeloid DCs (mDCs) and plasmacytoid DCs 
(pDCs), which can be subdivided based on their expression of blood DC antigens 
(BDCA). pDCs express BDCA-2 (CD303) and BDCA-4 (CD304), while the mDCs 
can be further subdivided as BDCA-1 (CD1c) or BDCA-3 (CD141) expressing. The 
latter subset was only recently described to represent the human counterpart to the 
mouse CD8+ DCs, known to have superior cross-presenting capacity (82-85). A CD14- 
CD16+ DC subset often termed non-classical monocyte, have also recently been 
identified. This subset shares characteristics with both monocytes and DCs (86-91). 
The mDCs as a whole have been shown to have a higher capacity for antigen uptake 
and presentation than pDCs. They are powerful inducers of TH1 responses by their 
capacity for IL-12 p70 production, and drive immune responses by secretion of TNF 
and IL-6 (66, 86, 87, 92-96). Different reports show slightly different data on the 
specific TLRs expressed on the DC subsets. However, most point to mDCs having 
some level of expression of TLR receptors 1-8 and 10, thereby being able to respond to 
a very wide variety of pathogens. In contrast pDCs express mainly TLR 7 and 9 
thereby responding specifically to viral infection (97). pDCs have a unique ability to 
produce high levels of type I interferons (IFN!/") which among many immune 
functions are important in anti-viral defenses (98-100). Through secretion of IFNs 
pDCs enhance the cytotoxicity of NK cells and CD8+ T cells, and also protect 
surrounding DCs from the cytopathic effects of many viruses (97). pDCs can also 
secrete IL-12 and IL-6, which in concert with the type I IFN help induce IFN$ 
production in T cells, and can promote memory B cell differentiation to promote anti-
viral Abs (101). All these effects help clear viral infections. Sadly, the potent effects of 
type I IFN can be turned against the host in a series of autoimmune conditions (102, 
103) and graft versus host disease (104), where pDCs are suspected instigators. In 
contrast, pDCs have also been shown, like mDCs, to be of vital importance in tolerance 
induction (reviewed by (105)). While mDCs are found throughout the body - in blood, 
lymphoid tissues and also in skin and mucosa, pDCs are more confined to blood, the 
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thymus and lymphoid tissue at steady state, but can migrate to sites of antigen exposure 
in inflammation (102, 106). 
 
5.4.2 DC subsets in the skin 
The DC subsets of the skin represent a heterogeneous group of cells, whose definite 
characteristics and functions are still under debate. The Langerhans cells (LCs) of the 
epidermis was the first subset of DCs to be identified in skin, and are currently the best 
characterized. They differ from most other DCs by their distinct expression of the C-
type lectin receptor langerin (CD207), and can be defined by unique cytosolic 
structures referred to as Birbeck granules (BG), where Langerin traffics to after antigen 
uptake (107). Langerin is also expressed in some dermal DC (dDC) subsets, but it is not 
clear whether these represent epidermal LCs in transition, or a unique dDC subset. LCs 
also express MHC class II, CD1a, CD205, and adhesion molecules CD11c and E-
cadherin (107). The latter is a key mediator of LC-keratinocyte adhesion (108). When 
activated, LCs downregulate E-cadherin, becoming free to migrate towards the afferent 
lymph. While much indicates that LCs develop from a common hematopoietic myeloid 
progenitor, and are replenished from blood, some studies have evoked questions as to 
whether LCs actually develop from a skin resident precursor (109-112). The dDCs, in 
contrast, do appear to be repopulated from blood only (110, 113). Origin is not the only 
question of debate concerning LCs, their function is also still under investigation. There 
is definite evidence that LC are strong activators of cellular immunity, by activation of 
CD4+ T cells in particular (114), but they have also been proven to be key mediators of 
tolerance (115-117). These functions need not be mutually exclusive, but the conditions 
under which these opposing function are elicited, and especially how we could replicate 
these conditions in vaccine strategies and treatments targeting the LCs, still needs to be 
elucidated. Another DC can be seen in epidermis, but in chronic inflammatory diseases 
only; the inflammatory dendritic epithelial cell (IDEC). These DCs do not express 
Langerin, and seem to differentiate from blood monocytes. They represent a more 
immature DC phenotype than the LCs, with strong antigen presenting capacity (118, 
119).  
                                                                                                                                              
In recent years several DC subsets in the dermis have been identified. Different 
phenotypical and functional classifications have been suggested, and there is still no 
definite nomenclature. The classification of both epidermal and dermal subsets is made 
more difficult by the inherent plasticity of DCs. Since the isolation of skin DCs affects 
their maturation status (120), and thereby their phenotype and function, different 
isolation protocols could result in different subsets. The inclusion criteria for DCs also 
vary and since there is no specific marker for dDCs, different studies often use different 
markers to identify them. However, dDCs are generally considered to express the C-
type lectins MMR (CD206), DEC 205 (CD205) and DC-SIGN (CD209). As discussed 
earlier, Langerin is expressed on one DC subset in the dermis, but it is not clear 
whether these cells represent a dermal resident DC, or migratory LC emigrated from 
the epidermis. Further, dDCs express varying levels of CD14 and CD1a. The dDCs 
expressing CD14 have been described to exhibit a more immature phenotype, possibly 
representing a precursor DC population (109). Interestingly, a recent study by Chu et al. 
introduces the concept of a CD141+ CD14+ CD1a- CD11clow CD1clow dDC, described 
as a competent inducer of T regulatory cells, capable of suppressing graft versus host 
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disease and anti-tumor immunity (121). In mouse models, dDCs have been shown to be 
able to replace LCs in induction of contact sensitization (122-124), and also to induce 
cytotoxic T cell responses to herpes simplex virus, and to leishmania, when LCs did not 
(125-127). This could imply that the LCs main function is tolerogenic, unless strongly 
stimulated, while dDCs would be more prone to induce immune responses. Given the 
anatomical location of the subsets, with the LCs at the interface of self and non-self, 
continuously exposed to the commensal flora of mucosal surfaces and skin, and the 
dDCs at sites where they should not be exposed to microbial antigens unless there has 
been a breach of the integrity of the body linings, this division would be fairly logical. 
But the evidence is still conflicting, and LCs have in other studies, using human DCs, 
been shown to be superior inducers of effector CD8+ T cell responses (128, 129). 
Several factors can contribute to the conflicting results. Apart from potential 
differences between the species, the technical difficulties of in vitro studies of DCs 
might also affect the results.   
                                                                                                                               
In the skin, as anywhere else in the body, the delicate balance of immunity and 
tolerance is sometimes disrupted, resulting in autoimmune disease. With DCs being at 
the heart of the control of this balance, their role in the pathogenesis, both instigation 
and propagation of disease, is an intensive field of study. DCs have been shown to 
migrate to sites of atopic dermatitis (130, 131) systemic lupus erythematosus (SLE) 
(132, 133), dermatomyositis (134), Sjögren’s syndrome (135), graft versus host disease 
(136), and psoriasis (106, 137), where a suggested mechanism whereby pDCs could 
drive the pathogenesis has also been published (30).  
 
5.5 DENDRITIC CELLS AS TARGETS AND TOOLS 
Since DCs are pivotal for both defense to pathogens and malignancies, and involved in 
autoimmune diseases, targeting DCs with drugs that can enhance or dampen their 
function may be a desirable strategy. Protein subunit vaccines contain adjuvants, i.e. 
substances that enhance and shape the immune responses to the vaccine. To elicit 
potent immune responses with vaccines to lethal pathogens like HIV, MTB, or 
Plasmodium falciparum (causing malaria), strategies of specifically targeting DCs with 
adjuvants or antigens, for instance by the use of selected TLR ligands or viral vectors as 
vaccine adjuvants, are being investigated. Apart from vaccination against microbes, 
DCs are suggested as potential mediators of cancer treatment through “vaccination”. 
This strategy involves the extraction of monocytes from a cancer patient, which are 
then differentiated into monocyte-derived DCs (MDDCs) in vitro, loaded with antigens 
from the patients own tumour, and then re-administrated to the patient. Such strategies 
are already in clinical trials (138). Apart from vaccination strategies, DCs are already 
indirectly targeted by general immunomodulatory treatments for many infectious and 
autoimmune conditions.  
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6 HUMAN IMMUNODEFICIENCY VIRUS 
6.1 THE HIV EPIDEMIC  
In 1981, an unusual clustering of patients diagnosed with Pneumocystis carinii 
pneumonia was recorded in Los Angeles, USA (139). Additional such cases, and 
eventually also increasing numbers of previously healthy patients presenting with other 
unusual diagnoses related to immunodeficiency, led to the unravelling of one of the 
worst plagues in modern time. Initially being predominantly spread among gay men 
and intravenous drug users in the western world, the epidemic was eventually fairly 
well controlled in these populations by intensive preventative work and efficient anti-
viral drugs that control the viral load and thereby limit the spread. Tragically, the virus 
meanwhile decimated Sub-Saharan Africa, where anti-virals are scarce and cultural 
beliefs limit behavioural interventions, killing millions and wiping out entire 
generations in some areas. Finally, the spread of HIV is currently decreasing in 
developing countries, due to improved availability of anti-retroviral drugs. However, 
there is still an urgent need for a preventative vaccine since no curative treatment is 
available, and current symptomatic treatments are paired with an array of side effects 
and are under the constant threat of viral resistance. Additionally, the global epidemic is 
not showing any signs of declining amongst MSM (men who have sex with men) or 
commercial sex worker populations (reviewed in (140)). 
                      
6.2 HIV-1 AND AIDS PATHOGENESIS, IN SHORT 
HIV is a retrovirus and part of the Lentivirus genus. As all retroviridae HIV has a RNA 
genome and carries the viral enzyme reverse transcriptase (RT). This enzyme is used 
by the virus to transcribe its RNA to DNA, which can then incorporate in the host 
genome. HIV exists in two main forms that infect humans, HIV-1 and HIV-2. The 
disease progression is slower with HIV-2 and it is also less transmissible. HIV-2 was 
first reported from West Africa, and is still spread mainly on the African continent 
(141, 142), while HIV-1 is the by far the most dominant form throughout the world. 
HIV-1 primarily infect CD4+ T cells by binding to the CD4 receptor and main co-
receptors CXCR4 and CCR5, but the virus can infect a great variety of host cells, 
including DCs (95, 143-148). The infection and severe depletion of CD4+ T cells are 
the main characteristics in the pathogenesis of HIV/AIDS. As the number of CD4+ T 
cells in the blood drop, the immune system gets increasingly impaired (149-151). When 
less than 200 CD4+ T cells/µl blood remains, the patient is diagnosed with acquired 
immune deficiency syndrome, or AIDS. At this stage multiple opportunistic diseases 
appear, the course of which is the usual cause of death of infected individuals. In some 
cases, these infections start to appear earlier, and the patient will receive an AIDS 
diagnosis once one of a list of several AIDS-defining opportunistic infections 
(including invasive Candida or CMV-infection, Pneumocystis carinii pneumonia, 
Kaposis sarcoma etc) appear (152). Infection of various other cell types is also of 
importance for symptoms in advanced disease, as well as factors in transmission and as 
“hide outs” (viral reservoirs) for the virus (144, 153-155). 
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6.3 DENDRITIC CELLS IN HIV-1 INFECTION AND AIDS 
DCs are resident at mucosal surfaces where primary infection usually takes place, and 
evidence suggests that they are targeted early in the course of infection (156-158). DCs 
express the receptors most commonly used by HIV-1 (CD4, CCR5 and CXCR4) and 
are susceptible to infection (146, 156, 159-165). When productively infected the DCs 
become a long-term source of infectious virions in the body. Transmission of such de 
novo synthesized virus from DCs is referred to as cis-transfer. Additionally, DCs can 
internalize the virus by CLR-mediated endocytosis without being productively infected, 
and act as “Trojan horses”, bringing the virus from the periphery to lymphocyte-rich 
areas were it is exocytosed and transmitted to CD4+ T cells (trans-infection) (20, 166, 
167) DCs can also facilitate infection of T cells by attracting them to sites of HIV 
exposure after HIV-1 stimulation of DC TLRs (reviewed in (168)), and it has also been 
suggested that DCs facilitate propagation of infection by tolerogenic effects (169-173). 
That said, DCs also have to capacity to induce adaptive immune responses to the virus 
(155, 174-178) and could therefore also have important functions in controlling the 
infection once established, although some conflicting studies have demonstrated that 
this capacity is reduced (179-181) compared to healthy individuals. Their ability to 
induce immune response to the virus could be of great importance in the development 
of vaccine strategies, but could potentially also be targeted in new treatment strategies. 
 
DCs are directly affected by HIV-1 infection, in that reduced numbers of both mDCs 
and pDCs are found in blood early in the infection (178, 182-184). While at least some 
mDC subsets can replenish after HAART, pDCs do not seem to recover as well (185-
188). Nonetheless, the levels of both DC subsets remain decreased in comparison to 
uninfected individuals (185). This might also be true for elite controllers (178) despite 
the fact that these patients have very low or undetectable viral loads and often 
unaffected T cell counts. The exact mechanism behind the depletion of DCs is not 
known. An increased rate of apoptosis (189, 190) and direct infection (179) have been 
suggested, but it has also been shown that DCs accumulate in lymphoid tissues, which 
may reflect a redistribution of DCs from the blood (191-194). The reduction of DCs 
could be important to HIV-1 pathogenesis, as the magnitude of the reduction of blood 
DCs in primary infection has been suggested to be a prognostic factor for the course of 
the disease (195). Interestingly, a recent observation indicated that severe pDC 
depletion in the blood of HIV-2 infected individuals is associated with a more 
attenuated form of the disease (196). Whether it is the actual depletion of blood DCs, or 
co-variations of factors contributing to both DC depletion and other manifestations, 
remains to be proven. Due to the fact that blood DCs are reduced, the question of 
functionality of DCs in HIV-1 infected individuals has been extensively studied. Some 
studies have demonstrated that there is reduced IFN! production in blood PBMCs and 
pDCs of infected individuals (185, 188, 197) while others have shown HIV and HIV-
infected cells to be potent inducers of IFN production in pDCs (178, 198-200) and IFN 
levels to be chronically elevated in HIV infected individuals (201-203). These results 
might seem contradictory, but they do not have to be. The mode of stimulus of the 
pDCs in experimental settings, the stage of disease in the subjects, and bystander 
effects of other cells in the culture might all play a role in shaping the results. It has also 
been suggested that immune exhaustion of the pDCs in vivo due to chronic activation 
renders them unreceptive to ex vivo stimulation, possibly explaining the discrepancy in 
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the results (204). mDCs have been described to have an abnormal immature phenotype 
in lymph nodes of HIV-1 infected individuals (172), but also to display 
hyperfunctionality with increased cytokine production in the blood, which could 
contribute to the chronic immune activation that is important in HIV-1 pathogenesis 
(178). The latter study showed the same result for pDCs. In conclusion, the activation 
status of DCs in HIV-1 seems to be altered, and it is possible that this has an effect on 
HIV-1 pathogenesis. 
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7 MATERIALS AND METHODS 
7.1 ISOLATION OF HUMAN DENDRITIC CELLS 
Presented below is a brief overview of the methods used in the studies included in this 
thesis. For more comprehensive descriptions, please see respective paper.  
 
7.1.1 Isolation of dendritic cells from skin  
In paper I, we first developed new methods to be able to study skin DCs, initially by 
refining previously described skin DC isolation protocols (205, 206). Skin samples of 
discarded skin from breast surgery were collected from Karolinska University Hospital. 
The skin was collected immediately after surgery and placed in complete media 
(RPMI; 10% fetal calf serum (FCS); glutamine; penicillin and streptomycin) with 
antifungal supplements. The skin was first cleared of subcutaneous fat and then cut in 
pieces about 3 to 5 cm in size. To allow access of dispase, which enzymatically digests 
the bindings of epidermis and dermis to enable separation of the layers, the skin has to 
be cut in thin (1-2 mm) slices. Traditionally, this was performed with a scalpel. To 
facilitate this very time consuming and laborious step of the protocol, we introduced the 
use of a skin graft mesher that slices the skin into thin nets, allowing the dispase to 
access the skin. The nets were incubated in dispase (GIBCO) for 90 min at 37 °C and 
5% CO2. The epidermis could then readily be separated from the dermis using sharp 
forceps. The epidermal and dermal sheets were washed and then incubated separately 
in complete media supplemented with Hepes buffer (GIBCO) and GM-CSF 
(PeproTech) to maintain a pH-stable physiological medium and to enhance migration, 
respectively. DCs that migrated into the media were harvested by filtering the media 
through a 70 µm cell strainer to obtain a single cell suspension. The cells were counted 
and used for experiments or further enriched by centrifugation using Ficoll-Paque Plus 
(GE Healthcare Biosciences AB, Uppsala, Sweden) density gradient (205). Trypan blue 
exclusion was used to measure cell viability. 
 
7.1.2 Generation of MDDCs 
The ability to produce MDDCs in vitro has been revolutionary in DC research, and lots 
of data have been generated using these cells. However, it is important to understand 
potential differences between MDDCs and primary subsets of myeloid DCs. To 
generate MDDCs for paper I, human PBMCs were isolated by Ficoll gradient 
centrifugation from buffy coats from healthy donor as previously described (205-207). 
Monocytes were isolated by plastic adhesion and cultured in complete media (as 
described earlier) supplemented with IL-4 (R&D Systems) and GM-CSF for six days, 
after which 90% of the cells had downregulated CD14, upregulated CD1a and HLA-
DR, and exhibited DC morphology. 
 
7.1.3 Isolation of blood pDCs and mDCs  
In paper II, primary DCs were purified from blood as described (208, 209). In order to 
obtain sufficient yields of DCs, high numbers of PBMCs were collected from healthy 
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donors by aphaeresis (Dept of Transfusion Medicine, Karolinska University Hospital). 
Lymphocytes and monocytes were then separated based on size and sedimentation by 
counterflow centrifugation elutriation, and pDCs and mDCs could then be isolated 
from the elutriated monocytes by anti-BDCA-4 (pDCs) and anti-CD1c microbeads 
(mDCs) (Miltenyi) and AutoMACS separation (Miltenyi). pDCs and mDCs were 
cultured in complete medium supplemented with IL-3 (R&D Systems) and GM-CSF, 
respectively. 
 
7.1.4 Phenotypic characterization by flow cytometry  
For identification and phenotyping of the cells in papers I and II, the cells were 
washed and stained for surface or intracellular receptors for 15 min at 4°C and washed 
as previously described (210). Different combinations of Abs, directly conjugated to 
the fluorescent dyes FITC, PE, PerCP, Cy5-PE or APC, were used. For intracellular 
staining, cells were fixed and permeabilized using BD Cytofix/Cytoperm kit (BD), 
according to the manufacturer's instructions, prior to staining. The cells were collected 
on a FACS Calibur flow cytometer (BD) and data was analyzed using Flow Jo software 
(Treestar Inc).  
 
7.2 FUNCTIONAL ASSESSMENTS OF DENDRITIC CELLS 
7.2.1 Antigen uptake assessment in MDDCs  
To study the antigen uptake capacity of various dendritic cell subsets in paper I, the 
model protein ovalbumin (OVA, an egg white protein) was used. OVA is frequently 
used to study uptake of particulate antigens in mammalian cells. We used OVA 
conjugated with Alexa 488 (OVA Alexa 488, Molecular Probes) to allow detection by 
flow cytometry or confocal microscopy. The MDDCs were pulsed with OVA Alexa 
488 at 37°C for up to 48 h. To study the affects of maturation on antigen uptake 
capacity, cells were stimulated by the Toll-like receptor (TLR)-ligand Poly I:C (TLR3), 
imidazoquinoline compound (TLR7/8), or LPS (TLR 4) or by TNF!, for 24-48 h 
before antigen exposure to induce maturation. To assess background binding of the 
antigen, cells were pulsed at 4°C in parallel to the uptake assays performed at 37 °C, 
since incubation at 4°C will reduce active uptake to a minimum and therefore illustrate 
how much antigen could be expected to bind to the outside of the cells and not 
represent true uptake. In addition, the internalization of OVA was confirmed by 
subsequently treating cells with trypsin (Sigma-Aldrich) to remove cell surface bound 
OVA. To study the pathways of OVA uptake, cells were pre-incubated with mannan or 
rottlerin (both Sigma-Aldrich) before exposure to OVA Alexa 488. Cells were analyzed 
by either flow cytometry or adhered to slides for confocal microscopy analysis. 
Untreated cells were also incubated with OVA Alexa 488, adhered to slides and stained 
with anti-EEA-1 (early endosome marker) or anti-LAMP-1 (lysosomal marker) to 
illustrate their processing in the cell matrix after uptake.  
 
7.2.2 Antigen uptake assessment in skin DCs  
(paper I) To assess the antigen uptake capacity of the various DC subsets in skin, OVA 
Alexa 488 or dextran (Oregon green 488, Molecular Probes), was added to the cells 
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either during migration or after the cells had completed their migration and been 
harvested. For antigen exposure during migration, OVA (mainly taken up via CLR-
mediated endocytosis) or dextran (known to be taken up by macropinocytosis) was 
added directly to the media in which the skin nets were incubated. The migrated cells 
were harvested after 48 h and analyzed for antigen uptake. Uptake could not be 
assessed at earlier time points since the migration was not complete until after 48 h. 
However, most of the uptake is likely to occur early after antigen exposure. 
Alternatively, harvested cells (incubated in media without OVA during their migration) 
were pulsed with OVA or dextran. These cells would be more mature at the time of 
antigen exposure. With both exposure procedures, the final concentration of antigen 
used was 0.1 µg/ml and the total time of antigen exposure 48 h. Antigen uptake was 
assessed by flow cytometry. 
 
7.2.3 Injection of antigen in skin explants  
To illustrate antigen uptake at earlier time points in paper I, we developed a skin 
explant model, where freshly removed skin samples were cleared of subcutaneous fat 
and cut manually with a scalpel to pieces of an area about 3x3 cm. The skin was then 
injected with either PBS, OVA Alexa 488 or dextran Oregon Green 488. Each explant 
was injected several times to make distribution of antigen as even as possible. 
Injections were made as close to the epidermis as possible to minimize leakage of 
injected antigen from the tissue into the media through the porous deep dermis. The 
tissue explants were incubated for 48 h in complete media to allow migration of the 
cells. The migrated cells were harvested and analyzed for antigen uptake by flow 
cytometry. For in situ analysis of antigen uptake in intact tissue, OVA Alexa 488 was 
injected into >1 cm2 explants. The pieces were incubated for 90 min at 37°C. Biopsies 
of the injection sites were thereafter taken and immediately put in the freezing media 
O.C.T. (Sakura Finetek) and frozen at -80 °C to be further analyzed for antigen uptake 
by confocal microscopy. 
 
7.2.4 In situ analysis of antigen uptake in skin explants and characterization of 
infiltrating cells in skin biopsies  
In paper I-III, snap frozen skin biopsies were cut to 8 µm sections by cryostat and 
fixed on slides. Prior to staining, the sections were permeabilized with saponin (Riedel-
de Haen). To prevent unspecific signals from the fluorescently labelled streptavidin, 
endogenous biotin or biotin-binding proteins were blocked using an Avidin-Biotin 
blocking kit (Vector Laboratories). Primary Abs (raised in mouse, goat or rat) were 
diluted in EBSS-saponin and applied for incubation overnight. In order to reduce non-
specific binding of the secondary biotinylated Abs, the tissue sections were blocked 
with rabbit or goat serum. The secondary biotinylated Abs (i.e. biotinylated rabbit anti-
mouse, rabbit anti-goat or goat anti-mouse) were diluted in EBSS-saponin and applied 
for 30 min. Finally the sections were incubated with Alexa 488- or Alexa 594-labeled 
streptavidin (Molecular Probes), diluted in EBSS-saponin, for 30 min. In paper III, an 
Alexa 594 anti-goat Ab was also used in some experiments. All incubations were 
performed in the dark at RT. After the final incubation, the sections were washed 
thoroughly with sterile water, dried and mounted using Vectashield mounting medium 
or SlowFade® Gold antifade regent, both containing DAPI for nuclear staining. 
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Multiparameter analysis of OVA uptake, cell surface receptor expression and nuclear 
staining was performed on a laser scanning confocal microscope (TCS SP2, Leica 
Microsystems) using either 20x/0.7 or 63x/1.3 objectives for sequential image capture 
z-series of each fluorochrome. Separate analyses of the image data were used to verify 
co-localization with DC cell surface markers and that the OVA Alexa 488 signals were 
sequestered in an intracellular compartment and not at the cell surface.  
In paper II and III, the immunoflourescent stainings were preformed only to 
characterize cells present in the sections, not to visualize antigen uptake. In these 
papers, the major analysis was performed on sections stained by 
immunohistochemistry. Primary antibodies were followed by secondary biotinylated 
antibodies (Abs) as above, but for immunohistochemical stainings the secondary Abs 
were detected with the peroxidase-based Vectastain Elite ABC kit (Vector), and the 
reaction developed by diaminobenzidine tetrahydrochloride (DAB) peroxidase 
substrate kit (Vector Laboratories). Cell nuclei were counterstained with Mayer’s 
Haematoxylin (Histolab Products). The sections were analyzed by a Leica DMR-X 
microscope (Leica Microsystems) coupled to computerized image analysis (Leica 
Qwin 5501W, Leica Imaging Systems), as described (211). Quantification of all 
markers was performed in the dermis except for Langerin, which was done in the 
epidermis only. Melanin-rich cells at the interface of the epidermis and the dermis were 
excluded from the analyses. 
 
7.3 STUDIES OF DC AFTER IN VIVO ANTIGEN INJECTION IN HUMAN 
SKIN 
7.3.1 Collection of human skin punch biopsies  
The study subjects for paper II and III were recruited in Cape Town, South Africa or 
San Francisco and Cleveland, USA. Exclusion criteria included previously diagnosed 
tuberculosis and/or presentations of one of several symptoms e.g. cough, chest pain or 
fever. TST was performed according to international standards and considered positive 
at #10 mm. Punch biopsies were taken as described (212) from the antigen injection 
site and a saline injected site on the opposite arm at 48 h and snap frozen. The skin test 
for C. albicans and mumps were performed in the same way, but considered positive at 
#5 mm, and only the Cleveland cohort was tested with these antigens. The methods for 
sectioning, staining and analysis of the biopsies is described in section 7.2.4. 
 
7.3.2 Stimulation of pDC with LL-37-DNA complexes  
In paper II, in order to study the affects of LL37-DNA complexes on DCs, either 
human DNA (Biochain) or CpG ODN (class B 10103, Coley) were co-incubated with 
LL37 (Innovagen) for 30 min at RT. pDCs were exposed to the complexes for 16 h at 
37°C. Cell free supernatants were then harvested and analyzed for IFN! production by 
ELISA (VeriKine TM) according to the manufacturers instructions, and used for 
culture experiments with mDCs. Stimulated pDCs were also set in co-cultures with T 
cells. 
UKPMC Funders Group Author Muscript UKPMC Funders Group Author 
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7.3.3 Functional assays of pDC effects on mDCs  
In paper II, supernatants from pDCs (at 1:1) stimulated by LL37-DNA or LL37-CpG 
complexes, or recombinant IFN! as a control, were added to cultures of mDCs. The 
mDCs were incubated for 24 h, washed, exposed to PPD-Alexa 488 and analyzed for 
PPD uptake and CD80/CD86 expression, to illustrate whether activated pDCs could 
affect the antigen uptake capacity of the mDCs. To investigate the affects on T cell 
stimulatory capacity by stimulated pDCs or mDCs, the subsets were co-cultured with 
unlabeled or CFSE-labeled, purified allogeneic CD4+ T cells. The T cells were then 
analyzed for detection of IL-2, TNF! and IFN$ expression by intracellular staining and 
FACS analysis after 16 h incubation or for assessment of proliferation by CFSE 
dilution after 5 days, as described (155, 213). Alternatively, proliferation was measured 
by thymidine incorporation as described (214). Luminex assays (Human Cytokine 10-
Plex Panel, Invitrogen) were also used for analysis of cytokines in supernatants from 
DC and DC:T cell cultures, and performed according to the manufacturers instructions 
and analyzed by Luminex 200TM system (Invitrogen). As a control, PPD only was 
used in several of these experiments to ensure no stimulatory effects were exerted by 
that alone.  
 
7.3.4 Evaluation of PPD uptake capacity  
To allow detection of uptake in paper II, PPD (Statens Serum Institut, Denmark) was 
labelled by Alexa 488 protein labelling kit (Molecular Probes). Isolated pDCs and 
mDCs were then pulsed with PPD Alexa 488 and analyzed by flow cytometry. 
Alternatively, monocyte-enriched populations (Rosette Separation, StemCell 
technologies) were exposed to PPD Alexa 488 and cells expressing CD1c, CD123 or 
CD141 were analyzed. For confocal microscopy imaging, sorted pDCs and mDCs were 
transferred to adhesion slides. 
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8 RESULTS AND DISCUSSION 
The studies in this thesis have all revolved around the functions of human DCs residing 
in, or infiltrating, the skin in health and HIV-1 infection. The specific aims were to first 
refine the isolation of skin DCs and to characterize the isolated subsets and their ability 
to internalize antigen. Further, in order to study skin DCs in vivo we took an approach 
to analyze the recruitment of DCs to antigen skin test sites, which represent examples 
of antigen administration in the skin. Finally, we examined whether this recruitment 
was affected in HIV-1 infected individuals. Below I will present and discuss highlights 
of our findings from papers I-III.   
 
8.1 ISOLATION OF DENDRITIC CELLS FROM HUMAN SKIN 
It is critically important to perform studies based on physiologically relevant primary 
human DCs, including skin DC subsets, and not solely in vitro derived DCs. However, 
studies using primary DCs are hampered by restrictions in existing isolation protocols. 
Hence, our first objective in paper I was to refine isolation procedures for skin DCs. 
With skin DCs being rare, large amounts of skin need to be processed to yield sufficient 
cells for experiments. At the onset of our studies, most available protocols were very 
time-consuming and laborious, much due to a step where the skin had to be cut 
manually by a scalpel into thin slices. This step is needed to prepare the skin for 
enzymatic disruption that enables separation of the epidermis and dermis so that higher 
yields can be obtained, and the DC populations from the various anatomical sites can 
be studied separately. The fact that the slicing step is time consuming and labour 
intensive is not only a practical but also a biological problem since prolonged in vitro 
handling of the DCs increases the risk of maturation of the cells. In clinical practice, an 
instrument called a skin graft mesher (Figure 5) is used to expand skin grafts for 
transplantation. This instrument contains built-in blades that cut the skin into a delicate 
net-like structure. This structure resembles the manually sliced pieces of skin. We 
therefore evaluated the use of the skin graft mesher in skin DC isolation protocols. We 
found that there were a number of advantages with the skin graft mesher. The slicing 
step was markedly faster, on average 10 times faster when processing small samples 
(10 g of skin) and even greater with larger samples. We also found that the net structure 
created by the skin graft mesher not only allowed for efficient enzymatic treatment of 
the skin, but also that the subsequent step where the epidermis is peeled off from the 
dermis was much faster. When using the skin graft mesher, the epidermis would often 
come off in large intact sheets instead of having to be peeled off in countless small 
pieces as with the manually cut pieces. After separation of the dermis and epidermis the 
respective sheets were cultured for 48 hours to allow migration of the DCs into the 
culture media (205, 215-219). The cells harvested by the skin graft mesher method did 
not differ in phenotype, number of cells per gram of donor-matched skin, or viability as 
compared to the manual slicing procedure.  
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Figure 5: a) Manual 
slicing of skin in thin 
pieces by scalpel and 
forceps. b-c) The skin 
graft mesher, and the net 
shape of skin that has 
been run through the 
machine. (from figure 1, 
paper I) 
 
 
 
 
 
 
8.1.1 Phenotypic characterization of isolated DC subsets 
In paper I, we also performed an extensive analysis of the phenotype of the cells that 
we harvested from the skin. By flow cytometry, the cells with high expression of HLA-
DR were further analyzed for a variety of DC markers. We found that the DCs isolated 
from epidermis consisted of a fairly homogenous population of Langerin+ CD1a+ 
CD11c+ DEC205+ DC-LAMP+/- CD123- DC-SIGN- CD14- LCs. In contrast, the subsets 
isolated from dermis represented a heterogeneous population of DCs. They all 
expressed CD11c, DEC205 and some degree of DC-LAMP, and lacked DC-SIGN and 
CD123. However, they showed varying expression of CD1a, and could therefore be 
separated into populations based on their level of CD1a expression (Figure 6a). The 
subset with the highest CD1a expression was found to co-express Langerin (Figure 6b). 
This led us to speculate that they represent migratory LCs that are in transition from 
epidermis through the dermis towards afferent lymph as suggested earlier (220, 221). 
CD14+ cells were present among the CD1adim and CD1a- dDC subsets which suggests 
that these cells might have a more monocyte/macrophage phenotype and function. 
DEC-205 expression was higher in the CD1ahigh/dim than in the CD1a- subset (Figure 
6b). 
 
 
Figure 6. a) Flow cytometric plots show the varying CD1a expression found on DC subsets harvested 
from epidermis (left) versus dermis (right). b) Bar graphs depict the expression of Langerin, CD14, DEC-
205 and DC-LAMP in dDCs based on their CD1a expression. (from figure 1, paper 1) 
 
Both the epidermal and dermal DC subsets expressed intermediate to high levels of 
maturation markers CD25, CD86 and CD83. 
 
There is limited knowledge about the dermal DC subsets. Several of the previously 
reported isolation procedures of DCs from dermis involve exclusion of Langerin or 
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CD14 expressing cells which leads to these cells being neglected in the analysis. Also, 
DC-SIGN has been shown to be downregulated after migration (222), while DC-
LAMP expression can be upregulated during maturation in all skin DCs (221), which 
would affect the analysis of migrated subsets. As discussed in the introduction, a 
common classification of dermal DC subsets does not exist, although several have been 
suggested (122, 128, 220, 223-227). A strict classification is complicated due to the fact 
that most of the phenotypic markers are not specific for DCs, or that the expression of 
the markers can change with maturation. There is also controversy as to the ontogeny 
of the various skin DC subsets, including the LCs. To this end, some of the dDC 
subsets have been suggested as precursor cells rather than independent subsets. A 
classification of dDCs based on CD1a expression has previously been suggested (225). 
Our data are in favour of this since we consistently in our experiments could see a clear 
division of three dDC subsets based on CD1a expression. Further, separating the DCs 
based on CD1a expression correlated to significant functional differences in antigen 
uptake capacity between the subsets. While we hypothesize that the CD1ahigh subset 
represents migratory LCs, additional studies are needed to further characterize the DC 
subsets in terms of origin and function. The fact that CD14 expression was the highest 
in the CD1adim subset, could support prior data showing that these cells represent 
precursors to other skin DC subsets (109).  
 
8.2 THE ANTIGEN UPTAKE CAPACITY OF DC SUBSETS 
8.2.1 Differential ability of antigen uptake by isolated skin DCs 
While mouse studies have contributed with a significant volume of data on the antigen 
uptake capacity of skin DCs, many of these results remain to be confirmed in the 
human system. To functionally examine the distinct DC subsets isolated from 
epidermis and dermis, we focused on how efficiently they could internalize antigen in 
paper I. DCs were exposed to the well-characterized antigen OVA either during their 
migration process, or after harvesting. We found that LCs isolated from the epidermis 
were much more efficient at internalizing OVA than donor-matched dDCs when the 
cells were exposed during migration. Both subsets were more efficient if exposed to 
OVA during migration than after (Figure 7a). These data may not be surprising as it is 
well known that mature DCs have reduced antigen uptake capacity (64, 66, 68), and 
LCs have been described to have a more immature phenotype than dDCs (220, 221). 
This could explain part of the difference between the antigen uptake capacity of LCs 
and dDCs, and also the fact that DCs exposed post-migration were less prone to antigen 
uptake, since incubation and migration in itself matures the DCs. A mature phenotype 
may also explain why the CD1ahigh Langerinhigh dDCs showed the lowest uptake 
capacity of the dDC subsets; given our hypothesis that these cells are epidermal LCs in 
transition is correct. LCs that migrate through the dermis would likely be activated and 
carry antigen. In fact, the uptake capacity of CD1ahigh Langerinhigh dDCs often matched 
that of LCs that were exposed to antigen after emigrating out of the skin. The CD1a- 
dDC subset, which possibly represents non-DC-HLA-DR+ cells, or a DC precursor, 
showed an intermediate uptake while the CD1adim cells were the superior dDC subset 
for internalizing OVA (Figure 7b).  
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Figure 7. a) OVA uptake by skin DCs exposed to OVA before and after migration. Immature MDDCs 
were included for comparison. B) OVA uptake in dDCs exposed during migration, shown in relation to 
their CD1a expression. (from figure 3, paper I) 
 
 
The functional differences in antigen uptake capacity could support a division of dDCs 
based on CD1a expression, but further studies of the cells phenotype and function are 
needed to elucidate whether there is biological relevance to such a division.  
 
8.2.2 In situ injection of OVA in skin explants 
Since in vitro handling induces maturation in DCs, we sought to develop a method to 
be able to study the DCs in an immature state. We therefore established a skin explant 
injection model in paper I, where we could track antigen uptake by these DC subsets 
in situ shortly after antigen administration. In human skin explants, we performed 
multiple shallow injections of OVA labelled with Alexa 488. The explants were 
placed in culture and the cells were allowed to migrate out of the explant for 
harvesting and analysis by flow cytometry. Since there is no separation of dermis and 
epidermis in this protocol, the cells emigrated from epidermis versus dermis could not 
be completely distinguished. However, based on the CD1a expression of the 
emigrated cells, we found that the cells harvested by this method closely resembled 
those of DCs harvested from dermis. The antigen uptake capacity of the DCs 
harvested from the explant model was higher than observed in the dDCs isolated by 
our mesher protocol. This suggests that the dDCs targeted in the explant model were 
in a more immature state when exposed to the antigen. This advantage makes the 
explant model a good complement to studies using the mesher isolation protocol, 
while the latter has the advantage of producing higher cell yields and definite 
separation of the epidermal and dermal DC subsets.  
                                                                                                                                        
To further characterize the uptake of antigen by intact skin DCs prior to migration 
and maturation, we injected skin explants with OVA Alexa 488 and collected 
biopsies of the injection sites shortly after administration (90 min). OVA+ cells were 
readily detected throughout the dermis, but most prominently in the superficial 
dermis close to the basement membrane. While a diffuse Alexa 488 signal was seen 
in the deep dermis (where the injection took place), it seemed like the OVA+ cells 
were migrating towards the lymphatic capillary plexus (i.e. natural DC migration 
routes) in both the upper, papillary dermis, and in the deep dermis. No or very few 
OVA+ cells were found in the epidermis, in line with the fact that the injection 
occurred in the deep dermis and that it is unlikely that antigen-bearing cells would 
enter the epidermis after the injection. The vast majority of cells showing OVA 
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uptake expressed HLA-DR, and several also expressed DC-SIGN (Figure 8). In these 
stainings, Langerin and CD1a expressing cells were most evident in the epidermis, 
consistent with the high expression of these markers in LCs. Some OVA+ CD1a+ 
cells, and rare OVA+ Langerin+ cells, were observed in the dermis, but the generally 
low CD1a expression observed on dDCs in this system could relate to difficulties in 
detecting dDCs with low CD1a expression above the autofluorescence in the tissues. 
 
  
 
Figure 8. Immunofluorescent stainings of skin biopsies taken from skin explants injected with OVA 
Alexa488. OVA uptake (green) is detected in a) DC-SIGN (red) and b) HLA-DR (red) expressing dDC. 
(from figure 5, paper I)  
 
We concluded that the in situ model could be used to study the first events in the skin 
after antigen exposure. However, since no recruitment of new cells into the tissue can 
occur, this model can not fully appreciate all the components of innate immune 
responses. Nonetheless, it has the potential to provide important clues as to what the 
primary target cells are for antigens or adjuvants administrated intradermally. 
 
8.2.3 Potential OVA uptake mechanisms by DCs 
To investigate the pathway(s) by which OVA is taken up by the DCs, we performed a 
series of experiments in paper I using mannan to block CLR-mediated endocytosis 
(68) and rottlerin to block macropinocytosis (228). Pre-incubation with mannan and 
rottlerin is necessary for these studies, and since there was no way to ensure the 
inhibitors would efficiently penetrate the skin, we had to perform the experiment using 
MDDCs. We found that both blocking strategies led to a significant reduction of OVA 
uptake. Mannan, known to block CLRs like the mannose receptor (MR/CD206), DC-
SIGN and Langerin, was the most potent inhibitor. MR is known to traffic antigen to 
stable early endosomes, while DC-SIGN also can deliver cargo to lysosomes. 
Macropinocytosed antigen, which uptake can be blocked by rottlerin, would also end 
up in lysosomes (35). Early endosomes express the marker EEA-1, while lysosomes 
express Lamp-1 (68, 71, 229). Since we were unable to perform the blocking 
experiments in skin DCs, we instead analyzed the co-localization of OVA and EEA-1 
versus Lamp-1. Skin explant biopsies were collected 90 min after OVA injection and 
stained to visualize potential co-localization. We observed co-localization with both 
EEA-1 and Lamp-1, indicating possible uptake by both endocytosis and 
macropinocytosis, although it was not as frequent as found in the control experiments 
using MDDCs. However, our data indicate that skin DCs might utilize several receptors 
and pathways to internalize OVA.  
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While our data confirmed co-localization of OVA and EEA-1, and OVA and LAMP-1, 
in the injection model, implying plural uptake mechanisms, we could not quantify the 
contributions of macropinocytosis versus endocytosis, due to the constraints on 
blocking studies in skin DCs.  
 
8.3 DC SUBSETS INFILTRATE THE TST REACTION 
As mentioned above, a significant disadvantage with our in situ explant model is that 
studies of recruitment of immune cells, including DCs, to the skin after antigen 
administration cannot be performed. Determining the infiltration patterns of DC subsets 
to the skin after antigen exposure and/or during inflammation is important for 
increasing the understanding of the innate immune mechanisms involved in the 
response to various pathogens, allergens, topical treatments or vaccine components 
targeting the skin. In this regard, samples of human skin after antigen exposure offer a 
unique opportunity to study recruitment of cells. In the work presented in paper II and 
III, we had the opportunity to perform studies using skin punch biopsies obtained from 
individuals who had received standard DTH-inducing skin tests. In paper II, healthy 
volunteers living in Khayelitsha Township, Cape Town, South Africa, an area highly 
endemic for tuberculosis, were recruited (230). Due to the high TB exposure in the 
area, all donors expressed a positive, "10 mm, TST. As described in section 4.5, TST is 
the most commonly used skin test in humans and monitors prior exposure to MTB or 
its vaccine. TST gives a measure of the cellular immunity and DCs have previously 
been postulated to play a role in TST reactions (231, 232). In paper II, we therefore 
started by analyzing the presence of various DC subsets in biopsies taken from the 
positive TST sites and compared that with the level of DCs in biopsies taken from 
saline injected control sites in the opposite arm of the same individuals. As expected, 
there was a significant increase in the cellularity of the skin in the TST reaction. This is 
a hallmark of inflammation. The presence of DCs was first evaluated by HLA-DR 
staining which showed that the positively stained area was significantly higher in the 
TST reaction than in saline-injected control sites. In line with that, several markers for 
myeloid DCs, including Langerin, DC-SIGN, CD11c, CD68 and CD141, were also 
significantly upregulated at the TST site compared to controls (Figure 9). This suggests 
that there is a rather robust infiltration of several DC subsets into the positive TST 
indurations. Interestingly, while the CD141+ cross-presenting DC subset was rarely 
detected in skin from the control site, it was consistently detected at the TST site. 
Infiltration of CD141+ DC in response to antigen delivery and inflammation in the skin 
had not earlier been described, and since they are potent stimulators of CD8+ T cell 
responses (84), they may play a particular role in presenting PPD to infiltrating CD8+ T 
cells. Their recruitment to skin might mean that there is a possibility of targeting these 
cells in transdermal vaccination strategies. Since our paper was published, a study has 
reported a skin resident CD141+ dDC with tolerance-inducing capacity, thus potentially 
important for maintaining skin homeostasis (121). Hence, as for many DC subsets, the 
tolerance-inducing versus immune-activating roles of this subset needs to be further 
elucidated. 
 
pDCs are rare in the skin at steady state (223). In accordance with this, CD123+ pDCs 
were rare or absent in controls, but we detected the presence of pDCs in all positive 
TST biopsies.  
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Figure 9. Expression of selected DC-markers (brown) in skin punch biopsies from saline-injected sites as 
well as positive TST sites. The cell nuclei are visualized in blue by haematoxylin counterstaining. 
 
Since CD123 is not entirely specific for pDCs, we also stained the tissues for another 
pDC marker, CD303 (BDCA-2). Again, we found very few if any CD303+ pDCs in 
the control sites and significantly more at the TST sites. Most CD303+ cells co-
expressed CD123. BDCA-2 is known to be downregulated in activated pDCs (224), 
which probably explains some of the lack of co-staining of CD123high and BDCA-2+. 
The recruitment of pDCs to the TST sites had not been previously shown either, and 
prompted our investigation of their role in this immune reaction. 
 
8.4 THE ROLE OF PDCS AT THE TST SITE 
As discussed earlier, pDCs are potent producers of IFN!/", hence their role in antiviral 
defences has been particularly explored (98). Indeed, pDCs have been shown to be 
recruited to the skin in viral infections such as herpes simplex (233, 234) and varicella 
(235, 236). They presumably have as important a role in anti-viral defences in the skin 
as elsewhere in the body. However, pDCs have also been shown to exert other 
immune-regulatory properties not involving pathogen responses (237). They have been 
described to be recruited to the skin not only in infection, but also to allergic contact 
hypersensitivity reactions (131) and to autoimmune skin manifestations in lupus 
erythematosus (132, 133) and psoriasis (102, 106). In the latter, infiltrating pDCs were 
shown to be activated and produce IFN!. Since we observed that pDCs were recruited 
to the TST site, we set up experiments aiming to reveal some of their roles in the DTH 
reaction. First, we stained for IFN! in the TST tissue, but were unable to detect any. 
However, we did find that the GTPase MxA, specifically induced by IFN!/" exposure 
(238, 239), was significantly expressed in the TST site, while it was undetectable in the 
saline controls. This strongly implied that there was production of IFN!/" in the 
positive TST reaction. Insufficient sensitivity of the IFN!/" staining or the time point 
(48 hrs) of the biopsy collection are probable explanations for the lack of IFN! 
detection. Assuming that the pDCs at the TST site were activated to produce IFN!, 
what activated them? The dogma has long been that pDCs respond with IFN! 
production in response to TLR stimulation by microbial invasion. However, the PPD 
mixture itself is designed to not evoke immune responses in naïve individuals. IFN! 
production in psoriatic lesions, a non-pathogen-containing yet inflammatory milieu, has 
been suggested to be induced by self-DNA or RNA from dying cells in complex with 
Saline      PPD                     Saline             PPD 
CD11c 
CD141 
Langerin 
CD123 
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the antimicrobial peptide LL37 (29, 30). We could detect strong upregulation of LL37 
and also high levels of Caspase-3, high-mobility group protein B 1 (HMGB-1) and 
lactate dehydrogenase (LDH) in the TST tissue – all indications of cell death with 
leakage of cell matrix proteins, most likely also including self nucleic acids, at the site. 
Therefore, this mode of activation could be present and lead to pDC activation at the 
TST site as well. In line with previous studies (29, 30) we found that phenotypic 
maturation and IFN! secretion could be induced in pDCs by exposure to complexes of 
LL37 and human DNA in vitro. mDCs did not respond to stimulation by LL37-DNA, 
but if exposed to supernatants from pDCs exposed to LL37-DNA the mDCs matured. 
Also, mDCs exposed to pDC supernatants showed significantly reduced capacity to 
stimulate allogeneic CD4+ T cell proliferation (Figure 10a-b). Neither of these effects 
could be reproduced by exposure of the mDCs to recombinant IFN! alone. Further, 
LL37/DNA-exposed pDCs directly suppressed T cell proliferation in pDC:T cell co-
cultures. In addition to reducing proliferation of T cells, mDCs exposed to pDC 
supernatants altered the profile of cytokine production in the T cells, reducing the 
production of IL-2 (Figure 10c), while production of TNF! and IFN$ remained 
unchanged, and IL-6 and IL-10 were elevated. Thus, pDCs activated by LL37/DNA 
complexes in the TST site may regulate immune activation by directly or indirectly 
skewing cytokine production and controlling proliferation of T cells. 
 
  
Figure 10. Reduced T cell stimulatory 
capacity of mDCs exposed to 
supernatants from pDC stimulated by 
LL-37/DNA complexes, seen as reduced 
proliferation of activated T cells, 
measured by CFSE dilution (a) and 
thymidine incorporation (b), as well as 
reduced cytokine production, measured 
as percentage of T cells staining 
positive for indicated cytokines by 
intracellular FACS staining (from figure 
3 and 5, paper II).  
 
                                            
 
In previous studies, pDCs have been shown to regulate the magnitude of the immune 
response, for example by limiting T cell proliferation (240) or inducing T regulatory 
cells (241, 242). pDCs have also been shown to have different immune-stimulatory 
capacities at different differentiation/activation stages (243-245). It is likely that the 
nature of the antigen as well as the cytokine milieu at the site of antigen exposure play a 
role in shaping the pDC function. Our results indicate that pDCs stimulated by LL37-
DNA complexes, that are very likely present at the TST site, affect mDCs to reduce 
their antigen uptake and become less potent in activating T cells, actually limiting T 
cell proliferation and skewing the cytokine profile of the T cells away from a strong 
effector profile. The stimulated pDCs also had a direct effect on T cell, limiting their 
proliferation. We therefore believe that the role of pDCs at the TST is, at least in part, 
to control and limit the inflammation. It is not clear how the immune-stimulatory and 
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immune-regulatory capacities of the pDCs in this setting would come together. 
Potentially a response initiated by the pDCs could, as it becomes chronic, be 
propagated by other mechanism while the role of the pDCs instead would change 
towards a more tolerogenic role. Interestingly, pDCs have been shown to exert 
tolerogenic functions in other DTH reactions, like graft versus host disease and 
tolerance to liver grafts (136, 244, 246), and in the maintenance of tolerance to food 
antigens (247), but in conflicting studies have also been shown to mediate graft-versus-
host disease (104). As for the specific roles and modes of recruitments of pDCs in the 
TST, further studies, preferably with varying kinetics, are required to decipher these 
mechanisms.  
 
8.5 DIFFERENTIAL PPD UPTAKE BY DC SUBSETS IN VITRO 
In paper II, we also characterized the interactions of PPD and different DC subsets. 
PPD consists of proteins from seven strains of MTB and is sterilized and tested to not 
induce immune responses in non-sensitized individuals (248). However, there have 
been some data showing that PPD can induce maturation of MDDCs (249). In our 
study, we performed a series of experiments exposing primary human DCs isolated 
from blood to PPD. Neither mDCs nor pDCs responded with maturation or cytokine 
production after exposure to even high concentrations of PPD in vitro. We also 
analyzed PPD uptake capacity by the DC subsets. We found that pDCs showed 
significantly lower uptake of PPD compared to both the conventional CD1c+ mDCs 
and the cross-presenting CD141+ DCs (Figure 11). The PPD uptake data are in line 
with earlier observations where pDCs have been shown to possess poorer uptake 
capacity of other antigens compared to the mDC subsets (250). 
 
Figure 11. PPD uptake in DC 
subsets isolated from blood, a) 
percentage PPD-Alexa 488+ 
DC in the various subsets and 
b) Alexa 488 MFI of mock 
(filled dark grey), pDC (black 
line), CD141+ DC (grey line) 
and mDC (filled light gray). 
(from figure 4, paper I)  
 
In conclusion, since pDCs showed much lower uptake of PPD their primary 
contribution in the TST reaction may not pertain to antigen processing and presentation 
to T cells. Instead, they may have an important bystander effect of conditioning 
surrounding mDC subsets. As discussed above, this bystander effect could consist of a 
suppressor function to restrain otherwise potentially harmful, excessive immune 
activation. 
 
8.6 DC RECRUITMENT TO SKIN TEST SITES IN HIV-1+ INDIVIDUALS 
AND AIDS PATIENTS 
As mentioned, the function (or dysfunction) of DCs in HIV-1 infection is not clear. 
However, there are multiple reports showing there is depletion of blood DC subsets in 
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HIV-1 infected individuals (discussed in more detail in section 6.3.). Antigen skin tests 
including TST are used to monitor the integrity of the cellular immune system during 
HIV-1 disease. The main objective of paper III was therefore to study whether the 
robust infiltration of DCs to TST sites as found in paper II could also be observed in 
HIV-1+ individuals. In addition, we extended our analyses to include alternative skin 
tests using antigens other than PPD.   
                                                                                                                                              
For the studies of paper III, biopsies from both HIV-1+ and HIV- individuals were 
collected. One of our study cohorts comparing TST responses was again recruited in 
Khayelitsha Township, Cape Town, South Africa. In addition, we included another 
cohort from the University Hospital of Cleveland, which received mumps and Candida  
albicans skin tests. C. albicans and mumps virus are examples of antigens that most 
people have pre-existing immunity to, and skin tests for these antigens are therefore 
often used in the assessment of cellular immune response capacity. Amongst the HIV-1 
infected individuals in all our cohorts, we had separate groups of subjects with 
asymptomatic HIV-1 infection and those with AIDS. All study subjects had a biopsy 
taken from the antigen test site as well as a control site.  
 
The stainings of the control skin biopsies revealed that the steady state levels of DC 
marker expression in HIV-1+ individuals did not differ from that of the healthy 
individuals. This data complement previous studies demonstrating unaffected 
Langerhans cell counts in HIV-1+ patients (251). Hence the reduction in blood DCs 
during HIV-1 infection does not seem to be reflected in the skin. As expected, there 
was a significant increase of mDC subsets and pDCs at the TST sites as opposed to the 
control sites. The recruitment of CD11c+ DCs including the CD141+ cross-presenting 
subset was significantly lower in HIV+ subjects than in healthy controls. In addition, 
there was also a significant decrease of the recruitment of CD303+ pDCs in the HIV-1+ 
cohort (Figure 12). The difference was most pronounced in AIDS patients.  
 
                                                                                                                  
Figure 12. Expression of selected DC subset markers in skin punch biopsies from TST sites of healthy as 
well as HIV-1+ individuals, including subjects with AIDS. - = control site, P = PPD injected site, P+ = 
AIDS patient with positive TST, P- = AIDS patient with negative TST. (from figure 1, paper III) 
 
As mentioned above, in paper III, we also performed a similar analysis of biopsies 
from healthy and HIV-1+ individuals that had received antigen skin tests based on 
antigens from C. albicans and the mumps virus. We found that the mumps virus skin 
test showed very similar results as the PPD test did, namely that there was a substantial 
recruitment of DC subsets in both healthy and HIV-1+ individuals in response to 
antigen injection, but that there was a trend toward lower DC levels in the HIV-1+ 
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group. In contrast, the results from the C. albicans skin tests implied the reverse pattern 
i.e. the DC recruitment seemed to be increased in the HIV-1+ individuals. As discussed 
below, we hypothesize that these differences can be explained by the magnitude of the 
T cell responses to the various antigens.  
 
8.7 DC INFILTRATION CORRELATES WITH THE LEVEL OF T CELL 
RECRUITMENT 
There was significant recruitment of CD3+ T cells in response to the TST (Figure 13a) 
in healthy individuals. Importantly, the number of recruited pDCs and mDCs at the 
TST sites correlated to the number of infiltrating CD3+ T cells (Figure 13b). By 
immunofluorescent double-stainings, DCs and T cells were found closely adjacent in 
the tissue.  
 
 
Figure 13. a) The recruitment of CD3+T cells was significantly impaired in HIV+ individuals. P indicates 
PPD injected site, as opposed to saline injected controls. P+ = AIDS patient with positive TST, P- = 
AIDS patient with negative TST.  B) The levels of infiltrating pDC, illustrated by both CD123 and CD303 
expression, and CD11c+ mDCs, significantly correlated to the CD3+ T cell infiltration, as shown by a 
correlation of the  % of stained area for both markers. 
 
We hypothesized that the level of T cells that infiltrated the site of the skin antigen test 
determined the DC recruitment. This would mean that when the frequency of antigen-
specific T cell response is high, more DCs would be recruited to the site of antigen 
injection. As studied more in detail in paper II, administration of the skin antigen tests 
per se does not induce any immune activity, but if there are antigen-specific T cells 
available they will accumulate at the site of injection which in turn induces substantial 
inflammation, with subsequent recruitment of additional immune cells, including DCs. 
Maintained C. albicans-specific T cell responses in asymptomatic HIV infection (252, 
253), as well as more preserved reactions to antigen skin tests compared to PPD and 
mumps (254) have been reported in HIV-1+ people. The comparably well-preserved C. 
albicans-specific T cell responses in the HIV-1+ individuals could relate to there being 
a higher level of exposure to C. albicans antigens in these people. It is well documented 
that there is increased permeability of the gut mucosa during HIV-1 infection, which 
results in translocation of endotoxins from the gut (255). This likely means that there is 
also translocation of C. albicans antigens, which could explain the elevated levels of 
Abs to C. albicans in HIV-1+ individuals (256). Thus, it is probable that there is 
increased exposure of antigens from C. albicans to the gut draining lymphatics, which 
could lead to persistent stimulation of memory T cell responses. In studies of blood T 
cell responses to various antigens in HIV-1+ individuals, the response to C. albicans 
has been shown to be of higher magnitude than that to several viral antigens (257). In 
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contrast, PPD-specific memory T cells have been shown to be preferentially depleted in 
HIV-1+ infection (258). Our findings that the T cell infiltration at the PPD injected test 
sites seem to be reduced compared to the C. albicans test sites are in line with these 
studies. As mentioned, the level of recruited DCs correlated with the T cell recruitment 
to the TST site, suggesting that the DC recruitment might be influenced by the T cell 
recruitment. The high recruitment of DCs in response to the C. albicans test supports 
this theory, and also indicates that the functional capacity of the DCs, regarding 
migration to the skin, is not impaired in HIV-1 infection. Instead the lower recruitment 
detected in the PPD test in the HIV-1 infected individuals compared to the healthy 
controls probably reflects the fact that the PPD-specific T cells are reduced and/or 
defective during HIV-1 disease.  Unfortunately, data on the levels of T cells specific to 
the different antigens in the study subjects were not available. However, CD45RA, 
CD45 RO and Ki-67 staining showed that most of the infiltrating cells expressed CD45 
RO and several of them expressed Ki-67 suggesting that the majority of infiltrating T 
cells were cycling memory T cells. Further studies addressing the kinetics of the 
recruitment of the various cell types are required to confirm whether the reduced DC 
infiltration reflects the depletion of blood DCs, indicates functional impairment 
affecting the migratory capacity of the DCs, or is secondary to reduced T cell 
recruitment. 
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9 CONCLUSIONS 
In the studies in paper I we developed protocols to facilitate isolation of skin DCs, and 
methods to target immature DCs in a skin explant model. We concluded that these 
experimental systems allowed us to perform studies on a larger scale than previously 
possible, and that antigen uptake by skin DCs could be visualized in situ. Our data 
indicated that in this system, most antigens are likely to be taken up by a heterogeneous 
group of dermal DC subsets. Taken together, paper I provided improved tools for 
studies of antigen exposure of skin DCs.  
 
In paper II, we showed that there was a robust and rapid infiltration of multiple DC 
subsets, including the cross-presenting CD141+ myeloid subset and pDCs, to the 
indurations induced by positive tuberculin skin tests. This is particularly interesting 
since several of these DCs do not normally reside in the skin. We found that 
components in the positive indurations, such as self-DNA leaking out from dying cells 
and the antimicrobial peptide LL-37, induced activation, including production of IFN!, 
of pDCs in vitro. We further showed that stimulation of mDCs by supernatants of 
LL37-DNA-activated pDCs, reduced both their antigen uptake capacity and ability to 
activate T cells. This led us to speculate that the role of the pDCs at the skin antigen test 
site is mainly regulatory.  
 
In paper III, we found that antigen skin test sites of HIV-1 infected individuals also 
had a substantial recruitment of DCs. In contrast to what has been reported in the blood, 
there was no reduction of resident skin DCs in the HIV-1 cohort at steady state. The 
level of DC recruitment to the antigen skin tests site correlated with the level of T cell 
infiltration. The data therefore suggested that mobilization of DCs to the skin is 
dependent on memory T cell activation and recruitment, rather than the DC count in 
blood, and that the blood DCs in HIV-1 infected individuals retain their capacity to 
migrate to a site of inflammation.  
 
In summary, we hope our studies have contributed some clues to the innate immune 
functions of various DC subsets in human skin. While there is still much to learn about 
the role of DCs in health and disease, every piece of the puzzle brings us closer to a 
better understanding, and immense knowledge has been gained since the fairly recent 
realization that there is significant complexity among the DC subsets and their 
functional specialization in the human immune system.  
 
!
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